| London Stock Exchange: ETX
e-Therapeutics Plc is a drug discovery and development company which provides evaluation services to investors and pharmaceutical companies, analyzing drug candidates to determine their indication, efficacy and tolerance properties. The company has a clinical pipeline of three drugs and is seeking new candidates for development at its Network Pharmacology Centre and its drugs include ETS2101, ETS6103, ETX1153a and ETX1153c. It possesses efficient proprietary methods for discovering new bioactive compounds, de-risking candidates against efficacy and safety, discovering combinations of compounds with specific therapeutic effects and discovering surprising new indications for existing compounds. e-Therapeutics was founded by Malcolm Young on October 15, 2001 and is headquartered in Newcastle-upon-Tyne, the United Kingdom.